Video

Metastatic urothelial carcinoma: Is addition of more therapies to treatment regimens beneficial?

Author(s):

Urology Times staff
Conference|ASCO Annual Meeting: Bladder Cancer and RCC

Shilpa Gupta, MD, discusses several recent studies in the metastatic urothelial carcinoma space.

In this video, Shilpa Gupta, MD, discusses how recent research appears to indicate that the addition of more agents is not beneficial to patients undergoing treatment for metastatic urothelial carcinoma. Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
1 expert is featured in this series.
Modern medical office interior with computer and examination table | Image Credit: © New Africa - stock.adobe.com
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
Jeffrey A. Albaugh, PhD, APRN, CUCNS, answers a question during a Zoom video interview
Amy M. Pearlman, MD, interviews Gia Ching on Zoom
Related Content
Anktiva targets expanded indication in US and global approvals in EU and UK
January 16th 2025

Anktiva targets expanded indication in US and global approvals in EU and UK

Hannah Clarke
The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial
January 14th 2025

Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial

Hannah Clarke
“In this phase 2 study, an image-guided adaptive strategy enabled radiotherapy dose escalation to over 86% of patients’ bladder tumors without significant increase in toxicity,” wrote the authors.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
January 10th 2025

CREST: Sasanlimab hits primary end point of EFS for NMIBC

Benjamin P. Saylor
Results from CREST will be presented at an upcoming medical conference.
FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC
January 10th 2025

FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC

Hannah Clarke
"We expect to initiate patient dosing in the second quarter of this year, with initial three-month [complete response] data to follow," says Doug Warner.
© 2025 MJH Life Sciences

All rights reserved.